TrialClinical pharmacokinetics2019

Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis.

Petra Jauslin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.